Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
The Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development market research report provides in-depth analysis of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.
What are the mechanisms of action of the Metabotropic Glutamate Receptor 4 pipeline drugs market?
The mechanisms of action of the Metabotropic Glutamate Receptor 4 pipeline drugs market are Metabotropic Glutamate Receptor 4 Agonist and Metabotropic Glutamate Receptor 4 Antagonist.
Metabotropic Glutamate Receptor 4 pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Metabotropic Glutamate Receptor 4 pipeline drugs market?
The routes of administration in the Metabotropic Glutamate Receptor 4 pipeline drugs market are oral and intravenous.
Metabotropic Glutamate Receptor 4 pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What is the key molecule type in the Metabotropic Glutamate Receptor 4 pipeline drugs market?
The key molecule type in the Metabotropic Glutamate Receptor 4 pipeline drugs market is small molecule.
Which are the key companies in the Metabotropic Glutamate Receptor 4 pipeline drugs market?
The key companies in the Metabotropic Glutamate Receptor 4 pipeline drugs market are Addex Therapeutics Ltd, Appello Pharmaceuticals Inc, Bio-Pharm Solutions Co Ltd, Bristol-Myers Squibb Co, Domain Therapeutics SA, and H. Lundbeck AS.
Metabotropic Glutamate Receptor 4 pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
| Mechanisms of Action | Metabotropic Glutamate Receptor 4 Agonist and Metabotropic Glutamate Receptor 4 Antagonist |
| Routes of Administration | Oral and Intravenous |
| Molecule Types | Small Molecule |
| Key Companies | Addex Therapeutics Ltd, Appello Pharmaceuticals Inc, Bio-Pharm Solutions Co Ltd, Bristol-Myers Squibb Co, Domain Therapeutics SA, and H. Lundbeck AS |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4).
- Reviews of pipeline therapeutics for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) therapeutics and enlists all their major and minor projects.
- Assessment of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4).
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.
Recently Viewed Reports
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.